Scientists uncover genomic tug of war that influences chemotherapy's effectiveness

Some patients with myelodysplastic syndromes, like acute myeloid leukemia, benefit from a chemotherapy drug called decitabine that stunts cancer growth. But many others are resistant to decatibine's effects or become resistant over time.

Related Keywords

Fanju Meng ,Patrick Murphy ,Wilmot Cancer Institute ,University Of Rochester Medical Center ,Environmental Health Science Center ,Rochester Medical ,Cancer Institute ,Biomedical Genetics ,Rochester Medical Center ,Assistant Professor ,Health Science Center ,Cancer ,Enomic ,Acute Myeloid Leukemia ,Breast Cancer ,Fell ,Chemotherapy ,Na ,Embryo ,Gene ,Ene Expression ,Genes ,Enetics ,Junk Dna ,Leukemia ,Myelodysplastic Syndromes ,Myeloid Leukemia ,Research ,Toxin ,